BACKGROUND: Anaplastic thyroid cancer ranks among the most lethal of all human malignancies. Its rarity and rapidly fatal course have made it a difficult cancer to both study and treat. Unfortunately, there has been little progress in the management and control of this malignancy. Anaplastic transformation, or the intratumoral evolution of anaplastic carcinoma from pre-existing differentiated thyroid cancer, has become a well-accepted process, despite a limited understanding of its underlying mechanisms. METHODS: It is through review of the literature that an understanding of the aggressive disease biology can be developed. The aim of this review is to evaluate the relevant clinical, pathologic, and molecular studies to develop an insight into the mechanisms that underlie the intratumoral molecular evolution of anaplastic thyroid carcinoma. RESULTS/ CONCLUSION: It is based on an understanding of this process that effective treatments for this aggressive malignancy are currently being developed. Copyright 2003 Wiley Periodicals, Inc.
BACKGROUND:Anaplastic thyroid cancer ranks among the most lethal of all humanmalignancies. Its rarity and rapidly fatal course have made it a difficult cancer to both study and treat. Unfortunately, there has been little progress in the management and control of this malignancy. Anaplastic transformation, or the intratumoral evolution of anaplastic carcinoma from pre-existing differentiated thyroid cancer, has become a well-accepted process, despite a limited understanding of its underlying mechanisms. METHODS: It is through review of the literature that an understanding of the aggressive disease biology can be developed. The aim of this review is to evaluate the relevant clinical, pathologic, and molecular studies to develop an insight into the mechanisms that underlie the intratumoral molecular evolution of anaplastic thyroid carcinoma. RESULTS/ CONCLUSION: It is based on an understanding of this process that effective treatments for this aggressive malignancy are currently being developed. Copyright 2003 Wiley Periodicals, Inc.
Authors: Ivelina Mineva; Wolfgang Gartner; Peter Hauser; Alexander Kainz; Michael Löffler; Gerhard Wolf; Rainer Oberbauer; Michael Weissel; Ludwig Wagner Journal: Cell Stress Chaperones Date: 2005 Impact factor: 3.667
Authors: Jae-Hui Kim; Ji Yun Jeong; An Na Seo; Nora Jee-Young Park; Moonsik Kim; Ji Young Park Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Tam N M Ngo; Trang T B Le; Thoa Le; Andrey Bychkov; Naoki Oishi; Chan Kwon Jung; Lewis Hassell; Kennichi Kakudo; Huy Gia Vuong Journal: Endocr Pathol Date: 2021-09-24 Impact factor: 3.943
Authors: J Akaishi; M Onda; J Okamoto; S Miyamoto; M Nagahama; K Ito; A Yoshida; K Shimizu Journal: J Cancer Res Clin Oncol Date: 2006-10-28 Impact factor: 4.553
Authors: Y Ward; R Lake; P L Martin; K Killian; P Salerno; T Wang; P Meltzer; M Merino; S-y Cheng; M Santoro; G Garcia-Rostan; K Kelly Journal: Oncogene Date: 2012-07-16 Impact factor: 9.867